Valuation: Colinz Laboratories Limited

Market Cap 11Cr 11.77L 10.29L 9L 9L 16.72L 16.98L 1.14Cr 44.14L 5.51Cr 44.19L 43.24L 19Cr P/E 2024
19.5x
P/E 2025 36.8x
Enterprise Value 6.3Cr 7L 6L 5L 5L 9L 10L 63.82L 24.81L 3.1Cr 24.84L 24.31L 11Cr EV / Sales 2024
0.43x
EV / Sales 2025 2.04x
Free-Float
31.44%
Yield 2024 *
-
Yield 2025 -
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
25/05 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
29/04 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
24/01 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
17/01 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
27/11 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
08/11 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
03/11 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/25/31 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/25/21 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
16/25/16 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
04/25/04 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day-5.00%
1 week+2.65%
Current month-6.88%
1 month+25.32%
3 months+77.42%
6 months+49.62%
Current year+44.60%
1 week 77.55
Extreme 77.55
87.44
1 month 53.11
Extreme 53.11
87.44
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 33.35
Extreme 33.35
88.7
5 years 15.55
Extreme 15.55
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 73 -
Director of Finance/CFO - 20/05/2019
Compliance Officer - 01/12/2025
Director TitleAgeSince
Director/Board Member 73 26/11/1990
Director/Board Member 33 08/08/2024
Director/Board Member 76 08/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%+2.65%+85.22%+121.89% 20.52L
+1.81%+2.25%+13.40%+84.45% 4.8TCr
-2.54%+3.72%+65.71%+113.61% 3.69TCr
+0.15%+1.26%-3.35%+45.56% 1.24TCr
+3.71%+3.56%+14.13%+97.20% 1.19TCr
+0.39%+0.58%+33.25%+119.07% 901.14Cr
+0.66%-0.57%+19.28%+45.55% 719.73Cr
+0.71%+1.75%+53.59%-7.09% 704.81Cr
+0.68%+2.63%+23.97%+235.28% 655.31Cr
+9.99%+32.94%-15.69%+27.08% 658.28Cr
Average +1.06%+4.08%+28.95%+88.26% 1.46TCr
Weighted average by Cap. +0.84%+3.35%+27.92%+89.56%

Financials

2024 2025
Net sales 7.03Cr 7L 6L 6L 6L 10.49L 10.65L 71.21L 27.68L 3.46Cr 27.71L 27.12L 12Cr 6.53Cr 7L 6L 6L 5L 10L 10L 66.12L 25.71L 3.21Cr 25.73L 25.18L 11Cr
Net income 48.67L 51.12T 44.69T 41.07T 38.28T 72.6T 73.7T 5L 2L 23.92L 2L 2L 82.44L 49.66L 52.16T 45.59T 41.9T 39.06T 74.08T 75.2T 5L 2L 24.41L 2L 2L 84.12L
Net Debt -6.43Cr -7L -6L -5L -5L -10L -10L -65.14L -25.32L -3.16Cr -25.35L -24.81L -11Cr -4.91Cr -5L -5L -4L -4L -7L -7L -49.73L -19.33L -2.41Cr -19.35L -18.94L -8.32Cr
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
65
Date Price Change Volume
03/26/03 ₹77.55 -5.00% 465
02/26/02 ₹81.63 -4.99% 10,439
01/26/01 ₹85.92 +3.17% 83,999
30/26/30 ₹83.28 +4.99% 2,776
29/26/29 ₹79.32 +4.99% 6,381
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock